Smart Money Is Betting Big In CRVS Options - Corvus Pharma (NASDAQ:CRVS)

Group 1 - Investors have taken a bearish stance on Corvus Pharma, with significant options activity indicating potential insider knowledge of upcoming events [1][2] - The overall sentiment among large traders is mixed, with 42% bullish and 50% bearish positions noted [2] - Recent options trading has shown a focus on a price range for Corvus Pharma between $8.0 and $25.0 over the last three months [3] Group 2 - The average open interest for Corvus Pharma options is 685.5, with a total trading volume of 3,960.00 [4] - Noteworthy options activity includes a mix of bullish and bearish trades, with significant call options indicating potential upward movement [7] - Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing products that target immune cell functions, including candidates like soquelitinib, Ciforadenant, and Mupadolimab [8] Group 3 - Analysts have set an average price target of $29.0 for Corvus Pharma, with individual targets ranging from $27 to $32 from various firms [10][11][12] - The current trading volume for Corvus Pharma is 9,635,837, with the stock price down by 6.21% to $20.08, suggesting it may be overbought [11]